A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)

Antonio Viúdez, Filipe L.F. Carvalho, Zahra Maleki, Marianna Zahurak, Daniel Laheru, Alejandro Stark, Nilofer Z. Azad, Christopher L. Wolfgang, Stephen Baylin, James G. Herman, Ana De Jesus-Acosta

Research output: Contribution to journalArticlepeer-review

Abstract

Pancreatic neuroendocrine tumor (PanNET) is a neoplastic entity in which few prognostic factors are well-known. Here, we aimed to evaluate the prognostic significance of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) by immunohistochemistry (IHC) and methylation analysis in 92 patients with resected PanNET and follow-up longer than 24 months. In multivariate analyses, ki-67 and our immunohistochemistry prognostic score (IPS-based on MGMT, NDRG-1 and PHLDA-3 IHC expression) were independent prognostic factors for disease-free-survival (DFS), while age and IPS were independent prognostic factors for overall survival (OS). Our IPS could be a useful prognostic biomarker for recurrence and survival in patients following resection for PanNET.

Original languageEnglish (US)
Pages (from-to)24950-24961
Number of pages12
JournalOncotarget
Volume7
Issue number18
DOIs
StatePublished - May 1 2016

Keywords

  • Immunohistochemistry
  • MGMT
  • NDRG-1
  • PHLDA-3
  • Pancreatic neuroendocrine tumor

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)'. Together they form a unique fingerprint.

Cite this